Evaxion Biotech A/S (NASDAQ:EVAX) Short Interest Update

Evaxion Biotech A/S (NASDAQ:EVAXGet Free Report) saw a large increase in short interest during the month of June. As of June 15th, there was short interest totalling 45,400 shares, an increase of 6.3% from the May 31st total of 42,700 shares. Based on an average trading volume of 45,900 shares, the short-interest ratio is currently 1.0 days.

Evaxion Biotech A/S Price Performance

EVAX opened at $3.15 on Friday. The business has a 50 day simple moving average of $3.47 and a two-hundred day simple moving average of $4.39. The firm has a market capitalization of $17.04 million, a price-to-earnings ratio of -0.73 and a beta of -0.28. Evaxion Biotech A/S has a one year low of $2.26 and a one year high of $13.82.

Evaxion Biotech A/S (NASDAQ:EVAXGet Free Report) last announced its earnings results on Tuesday, May 28th. The company reported $0.03 earnings per share (EPS) for the quarter. The firm had revenue of $0.05 million during the quarter. As a group, sell-side analysts expect that Evaxion Biotech A/S will post -0.1 EPS for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Evaxion Biotech A/S stock. Beacon Capital Management LLC increased its stake in Evaxion Biotech A/S (NASDAQ:EVAXFree Report) by 606.8% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 48,633 shares of the company’s stock after buying an additional 41,752 shares during the period. Beacon Capital Management LLC owned 0.17% of Evaxion Biotech A/S worth $33,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 11.04% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on EVAX shares. LADENBURG THALM/SH SH raised Evaxion Biotech A/S from a “neutral” rating to a “buy” rating and set a $8.00 target price for the company in a research note on Tuesday, April 2nd. HC Wainwright reaffirmed a “buy” rating and set a $14.00 price target on shares of Evaxion Biotech A/S in a research report on Tuesday, June 4th.

Get Our Latest Research Report on Evaxion Biotech A/S

About Evaxion Biotech A/S

(Get Free Report)

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers.

Featured Articles

Receive News & Ratings for Evaxion Biotech A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evaxion Biotech A/S and related companies with MarketBeat.com's FREE daily email newsletter.